MIRRORNCT06074510
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 10 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 14 words Show 5 more changesShow less
- Trial completed
- Enrollment target: estimated 274 to confirmed 279
- Primary and study completion dates changed from estimate of Sep 2026 to Aug 28, 2026
- Secondary endpoints: details revised at 3 of 8 entries
- Site details revised at 1 of 14 sites
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary and study completion dates: Nov 2026 to Sep 2026
- Site details revised at 14 of 14 sites
- Minor Primary and study completion dates pushed to Nov 2026
- Site contacts updated at 14 of 14 sites
- Notable Primary completion date: Dec 2024 to Jul 2026
- Study sites: 10 to 14
- Study completion date: Jan 2026 to Aug 2026
- Minor Study sites: 5 to 10v6
Show 4 earlier versionsHide 4 earlier versions
- Minor Study sites: 3 to 5v5
- Minor Start date changed from estimate of Feb 2024 to Feb 8, 2024v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 3
- Notable Start date: Dec 2023 to Feb 2024
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Detection rate
Timeframe: Day 1
Secondary (8)
Change in intended patient clinical management
True detection rate
Correct localization rate
Positive predictive value of PYLARIFY
Sensitivity of PYLARIFY
Show 3 moreShow less
Specificity of PYLARIFY
Negative predictive value of PYLARIFY
Number of participants with Adverse Events
Arms and interventions
PYLARIFY PETExperimental
Drugs: Piflufolastat F 18 Intravenous Solution [PYLARIFY]
Sites
14 sites in 1 country